770 related articles for article (PubMed ID: 30941670)
1. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
5. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA as a post-treatment surveillance strategy: current status.
Burgener JM; Rostami A; De Carvalho DD; Bratman SV
Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
[TBL] [Abstract][Full Text] [Related]
7. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
8. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
[TBL] [Abstract][Full Text] [Related]
9. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA.
Semenkovich NP; Szymanski JJ; Earland N; Chauhan PS; Pellini B; Chaudhuri AA
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349125
[TBL] [Abstract][Full Text] [Related]
10. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ; Nabet BY; Alizadeh AA; Diehn M
Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
[TBL] [Abstract][Full Text] [Related]
11. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
13. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Chen Y
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
[TBL] [Abstract][Full Text] [Related]
14. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
15. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM; Soo J; Co Ting Keh L; Alig S; Chabon JJ; Sworder BJ; Schultz A; Jin MC; Scherer F; Garofalo A; Macaulay CW; Hamilton EG; Chen B; Olsen M; Schroers-Martin JG; Craig AFM; Moding EJ; Esfahani MS; Liu CL; Dührsen U; Hüttmann A; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
Nat Biotechnol; 2021 Dec; 39(12):1537-1547. PubMed ID: 34294911
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
17. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
19. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
20. cfDNA-Based NGS IG Analysis in Lymphoma.
Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M;
Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
